Update on Nasodine Trial and Forward Plans

  03 Oct 2023

Firebrick Pharma Limited announced that the independent preliminary investigation into the Phase 3 trial results of Nasodine Nasal Spray (“Nasodine”) (refer ASX announcement 13 September 2023) has not revealed any systematic error or other data issue that could explain or disclaim the reported results. The preliminary investigation phase has now been closed to avoid additional…

Read More